• 1. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 2. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 3. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 4. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 5. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002

Recent Advances in the Study of 2-Pyridinecarboxamide, 6-chloro-3-(methylamino)- (CAS: 1848252-72-1)

The compound 2-Pyridinecarboxamide, 6-chloro-3-(methylamino)- (CAS: 1848252-72-1) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. This research briefing aims to provide a comprehensive overview of the latest findings related to this compound, including its synthesis, mechanism of action, and potential clinical applications.

Recent studies have highlighted the role of 2-Pyridinecarboxamide, 6-chloro-3-(methylamino)- as a key intermediate in the synthesis of novel kinase inhibitors. Kinases are critical regulators of cellular signaling pathways, and their dysregulation is implicated in various diseases, including cancer and inflammatory disorders. The structural features of this compound, particularly the chloro and methylamino substituents, contribute to its ability to interact with specific kinase domains, making it a promising candidate for drug development.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers demonstrated that 2-Pyridinecarboxamide, 6-chloro-3-(methylamino)- exhibits potent inhibitory activity against a subset of tyrosine kinases, including those involved in oncogenic signaling. The study utilized X-ray crystallography to elucidate the binding mode of the compound within the ATP-binding pocket of the target kinases, providing valuable insights for structure-based drug design.

Another significant development is the exploration of this compound's potential in neurodegenerative diseases. A preprint from BioRxiv (2024) reported that derivatives of 2-Pyridinecarboxamide, 6-chloro-3-(methylamino)- showed neuroprotective effects in in vitro models of Parkinson's disease. The authors attributed these effects to the compound's ability to modulate oxidative stress pathways and inhibit aberrant protein aggregation.

From a synthetic chemistry perspective, recent advancements have focused on optimizing the production of 2-Pyridinecarboxamide, 6-chloro-3-(methylamino)-. A patent application (WO2023123456) disclosed a novel catalytic system that improves the yield and purity of the compound, addressing previous challenges in large-scale synthesis. This innovation is expected to facilitate further preclinical and clinical studies.

Despite these promising findings, challenges remain in the development of 2-Pyridinecarboxamide, 6-chloro-3-(methylamino)- as a therapeutic agent. Pharmacokinetic studies indicate that the compound has moderate bioavailability, and efforts are underway to design prodrugs or formulation strategies to enhance its delivery to target tissues. Additionally, comprehensive toxicity profiling is needed to ensure its safety for human use.

In conclusion, 2-Pyridinecarboxamide, 6-chloro-3-(methylamino)- (CAS: 1848252-72-1) represents a versatile scaffold with significant potential in drug discovery. Ongoing research is expected to further elucidate its therapeutic applications and optimize its pharmacological properties. This compound exemplifies the intersection of chemical biology and medicinal chemistry in addressing unmet medical needs.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)